Real-world four-year functional and surgical outcomes of Rezum therapy in younger versus elderly men.

Michael Zhu Mustufa Babar Noah Hawks-Ladds Marc-Mina TawfikJustin LoloiKevin F LabagnaraRahman SayedKevin TangAzizou SalamiSandeep SinghJaskirat SinghMatthew InesNazifa IqbalMichael Ciatto

Published in: Prostate cancer and prostatic diseases (2023)

There were no significant differences in IPSS, QoL, or AEs between elderly and younger men over 4 years following Rezum, suggesting comparable benefits and risks. Future research is warranted to clarify the impact of Rezum on Qmax in elderly men.

Keyphrases

middle aged
community dwelling
stem cells
current status
human health
risk assessment
mesenchymal stem cells
bone marrow
smoking cessation